Health Canada has accepted US-based Sucampo Pharmaceuticals’ New Drug Submission (NDS) for Amitiza (lubiprostone), 24mcg capsules, to treat chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
{iframe}http://www.pharmaceutical-business-review.com/news/health-canada-accepts-sucampos-new-drug-submission-for-constipation-drug-amitiza-050115-4481116{/iframe}